Efficacy and safety of Lianhuaqingwen capsules in high-risk common type COVID-19 pneumonia: A multicenter retrospective study

Abstract

Objective: To evaluate the clinical safety and efficacy of Lianhuaqingwen (LHQW) capsules in patients with high-risk common type COVID-19 pneumonia. Methods: A retrospective multicenter study on 383 high-risk common type COVID-19 pneumonia cases was conducted. Patients were categorized as the standard treatment (SDT) group (n=168) and the LHQW+SDT group (n=215). The primary endpoint was the rate of symptom (fever, fatigue, coughing) recovery and the secondary endpoints included the time to symptom recovery, the proportion of patients with improvement in chest CT images, the proportion of patients with clinical cure, the timing and rate of negative conversion of SARS-CoV-2 RNA assay. Results: The recovery rate was significantly higher in the LHQW+SDT group as compared with the SDT group (89.7% vs. 72.0%, P<0.01). The combined use of LHQW+SDT also showed shorter time for symptom recovery, as well as shorter time for individual symptom of fever, fatigue and coughing recovery than use of SDT alone. A higher proportion of patients in the LHQW+SDT group with improvements in chest CT images and clinical cure (77.7% vs. 57.1%, P<0.01) but the proportion of patients deteriorating to severe cases (1% vs. 25%, P<0.01) in this group was significant lower than those in the SDT group. No significant difference in negative conversion rate of viral assay results was observed (76.8% vs. 75.0%, P>0.05). No serious adverse events were reported. Conclusions: LHQW capsules could be recommended to ameliorate clinical symptoms and reduce the rate of deteriorating to severe cases for high-risk common type COVID-19 pneumonia.

Keywords

Lianhuaqingwen capsules / COVID-19 pneumonia / High-risk common type / Clinical efficacy

References

[1] Seyed Hosseini E, Riahi Kashani N, Nikzad H, Azadbakht J, Hassani Bafrani H, Haddad Kashani H. The novel coronavirus disease-2019 (COVID-19): Mechanism of action, detection and recent therapeutic strategies. Virology 2020; 551(2020):1-9.

[2] Hui DS, I Azhar E, Madani TA, Ntoumi F, Kock R, Dar O, et al. The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health - The latest 2019 novel coronavirus outbreak in Wuhan, China. Int J Infect Dis 2020; 91(2020):264-266.

[3] Tomazini BM, Maia IS, Cavalcanti AB, Berwanger O, Rosa RG, Veiga VC, et al. Effect of Dexamethasone on days alive and ventilator-free in patients with moderate or severe acute respiratory distress syndrome and COVID-19: The CoDEX randomized clinical trial. JAMA 2020; 324(13):1307-1316.

[4] Mo P, Xing Y, Xiao Y, Deng L, Zhao Q, Wang H, et al. Clinical characteristics of refractory coronavirus disease 2019 in Wuhan, China. Clin Infect Dis 2021; 73(11):e4208-e4213.

[5] Mallick AK, Ahsan M. Impact of COVID-19 on different organ systems and prognosis: A scoping review. J Acute Dis 2021; 10(1):1-7.

[6] Tüzün H, Özbaş C, Budak B, Altunay G, Aksakal FNB. Patterns in the relationship between acute COVID-19/long COVID-19 and quality of life: A cross-sectional study of patients attending a tertiary care hospital in Turkey. Asian Pac J Trop Med 2022; 15(6):274-282.

[7] Pinzón MA, Ortiz S, Holguín H, Betancur JF, Arango DC, Laniado H, et al. Dexamethasone vs. methylprednisolone high dose for COVID-19 pneumonia. PLoS One 2021; 16(5):e0252057.

[8] Hu K, Guan WJ, Bi Y, Zhang W, Li L, Zhang B, et al. Efficacy and safety of Lianhuaqingwen capsules, a repurposed Chinese herb, in patients with coronavirus disease 2019: A multicenter, prospective, randomized controlled trial. Phytomedicine 2021; 85(2021):153242.

[9] Meo SA, Meo AS, Al-Jassir FF, Klonoff DC. Omicron SARS-CoV-2 new variant: Global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci 2021; 25(24):8012-8018.

[10] Zhang X, Cao D, Liu J, Zhang Q, Liu M. Efficacy and safety of Lianhua Qingwen combined with conventional antiviral Western Medicine in the treatment of coronavirus disease (COVID-19) in 2019: Protocol for a systematic review and meta-analysis. Medicine (Baltimore) 2020; 99(30):e21404.

[11] Zeng M, Li L, Wu Z. Traditional Chinese medicine Lianhua Qingwen treating corona virus disease 2019(COVID-19): Meta-analysis of randomized controlled trials. PLoS One 2020; 15(9):e0238828.

[12] Li R, Hou Y, Huang J, Pan W, Ma Q, Shi Y, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020; 156(2020):104761.

[13] World Medical Association. World Medical Association Declaration of Helsinki: Ethical principles for medical research involving human subjects. JAMA 2013; 310(20):2191-2194.

[14] Chen Q, Yang Q, Fang Y, Chen G, Lv X. Potential benefits of precise corticosteroid therapy for critical COVID-19. Respir Physiol Neurobiol 2022; 297(2022):103813.

[15] Liu L, Qu H, Li JJ, Yang YW, Zeng QX, Gong YW, et al. Effectiveness of methylprednisolone therapy in patients with a high-risk common type of COVID-19 pneumonia: A retrospective cohort study. Clin Exp Med 2022; 22(3):487-497.

[16] Taghavi M, Shokri A, Niloofar P, Poorbarat S, Mollazadeh S, Milani H. Chest CT features in COVID-19 patients: A systematic review and meta-analysis. J Acute Dis 2021; 10(5):179-189.

[17] Ren JL, Zhang AH, Wang XJ. Traditional Chinese medicine for COVID-19 treatment. Pharmacol Res 2020; 155(2020):104743.

[18] Lan XF, Olaleye OE, Lu JL, Yang W, Du FF, Yang JL, et al. Pharmacokinetics-based identification of pseudoaldosterogenic compounds originating from Glycyrrhiza uralensis roots (Gancao) after dosing LianhuaQingwen capsule. Acta Pharmacol Sin 2021; 42(12):2155-2172.

[19] Zheng L, Su J, Zhang Z, Jiang L, Wei J, Xu X, et al. Salidroside regulates inflammatory pathway of alveolar macrophages by influencing the secretion of miRNA-146a exosomes by lung epithelial cells. Sci Rep 2020; 10(1):20750.

[20] Ho TY, Wu SL, Chen JC, Li CC, Hsiang CY. Emodin blocks the SARS coronavirus spike protein and angiotensin-converting enzyme 2 interaction. Antiviral Res 2007; 74(2):92-101.

[21] Xiao M, Tian J, Zhou Y, Xu X, Min X, Lv Y, et al. Efficacy of Huoxiang Zhengqi dropping pills and Lianhua Qingwen granules in treatment of COVID-19: A randomized controlled trial. Pharmacol Res 2020; 161(2020):105126.